Translational medicine approach to drug development in osteoporosis: Thinking beyond BMD

摘要

Meticillin-resistant Staphylococcus aureus skin and soft tissue infections are an increasing challenge for clinicians and healthcare organisations. Healthcare-associated MRSA, affecting older, compromised patients, presents in both the community and hospital and contrasts with the rarer true community-associated MRSA, which affects healthy young people. Newly licensed agents are now in use in many UK hospitals and other agents are in the advanced stages of development. How these new agents should be optimally deployed is uncertain, but prudent use to safeguard future treatment options seems wise at the present time.